Trials / Terminated
TerminatedNCT02193490
DNase Treatment for Dry Eyes
Safety and Efficacy Of Recombinant Human Deoxyribonuclease Eye Drops In Patients With Sjogren's and Non-Sjogren Dry Eye Disease
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- University of Illinois at Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the tolerability and preliminary efficacy of DNase eye drops in patients with Sjogren's and Non-Sjogren Dry Eye Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DNase | DNase 0.1% eye drops four times a day for 8 weeks |
| DRUG | Vehicle | Drug vehicle eye drops four times a day for 8 weeks |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2017-10-11
- Completion
- 2017-10-11
- First posted
- 2014-07-17
- Last updated
- 2020-01-18
- Results posted
- 2019-11-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02193490. Inclusion in this directory is not an endorsement.